Response to: “Commentary on: phosphodiesterase type 5 inhibitors do not prevent curvature progression but shorten pain duration in the active phase of Peyronie’s disease: a retrospective cohort study”
Crossref DOI link: https://doi.org/10.1038/s41443-024-00872-z
Published Online: 2024-03-22
Published Print: 2024-05
Update policy: https://doi.org/10.1007/springer_crossmark_policy
Durukan, Emil http://orcid.org/0000-0001-9221-8944
Jensen, Christian Fuglesang Skjødt
Fode, Mikkel
Text and Data Mining valid from 2024-03-22
Version of Record valid from 2024-03-22
Article History
Received: 26 February 2024
Revised: 4 March 2024
Accepted: 4 March 2024
First Online: 22 March 2024
Competing interests
: The authors declare no competing interests.